US Biosecure Act boosts Indian CDMOs

The US Biosecure Act is making it harder for companies to do business with China in the biotech sector.

This is giving Indian drug makers a chance to step in and take over some of the business.

Piramal Pharma, one of these Indian companies, is already seeing some interest from customers.

However, they say it will take some time before they see a real increase in revenue.

This is because the changes in the supply chain are happening slowly.

So, while there's a big opportunity, it's not going to happen overnight.